Modano's Tavern on the Green Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Modano's Tavern on the Green

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Modano who wrote (127)	5/28/1998 11:03:00 AM
From: FNS	Read Replies (1) of 154

Modano: Re: <<What is your take on this stock in the long term? Do you concur with the $70/share estimate? It looks like things have been pretty volatile. Any ideas why?>> 1. Long term I'm sure that CNTO will do well. But the $70 target is based on home runs with various Reopro, Retavase, and Avakine revenues. 2. The stock has certainly been volatile, perhaps like most biotechs. Not been too successful in trying to call the shots when to sell or buy more so I've decided to stay the course for another 1-2 years and then run....am retired and will look other other ventures. But do enjoy the game! From a TA and business fundamental perspectives I think the stock is a buy in here, and look forward to FDA approval of Avakine. Certainly the stats looks good and Crohn's patients can only benefit! (IMHO) Ciao! FNS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next